{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:37:33Z","timestamp":1779212253620,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005977","name":"Kaiser Permanente","doi-asserted-by":"publisher","award":["The Permanente Medical Group Delivery Science Gran"],"award-info":[{"award-number":["The Permanente Medical Group Delivery Science Gran"]}],"id":[{"id":"10.13039\/100005977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Preoperative invasive nodal staging is standard of care for early-stage non-small cell lung cancer (NSCLC). Complications and delays in care are not negligible and diagnostic accuracy varies. In our system, invasive nodal staging is performed for clear radiographic indications (node &gt;\u20091.0\u00a0cm short axis or standardized uptake value &gt;\u20093.0, tumor &gt;\u20094.0\u00a0cm). This study assessed whether unexpected mediastinal upstaging was less common in patients receiving preoperative invasive nodal staging.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective study evaluated nodal upstaging, defined as pathological N2 or IIIA+ disease, based on receipt or non-receipt of invasive nodal staging. Clinical stage I\u2013II NSCLC patients who underwent resection (2009\u20132019) were identified from our cancer registry. Stage and preoperative nodal staging information were confirmed through chart review. Associations between patient characteristics, invasive nodal staging receipt, and clinical to pathological stage changes were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among 2576 patients, 18.7% (<jats:italic>n<\/jats:italic>\u00a0=\u00a0481) underwent invasive nodal staging. After resection, 6.2% of all patients had nodal upstaging and 24.9% had TNM upstaging. Only 0.3% (<jats:italic>n<\/jats:italic>\u00a0=\u00a09) were upstaged to N2 and 0.5% (<jats:italic>n<\/jats:italic>\u00a0=\u00a013) were upstaged to IIIA+. Lack of preoperative nodal sampling was not associated with N2 or IIIA+ upstaging. Findings were consistent in subanalyses of patients with surgical specimens meeting Commission on Cancer nodal sampling criteria and with clinical IB+ disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Although most patients did not undergo invasive nodal staging, &lt;1% had unexpected N2 on surgical pathology. There was no association between lack of preoperative invasive nodal sampling and N2 nodal upstaging. Preoperative invasive nodal staging did not increase pathologic N2 nodal upstaging in early-stage NSCLC patients in our integrated health system.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1245\/s10434-025-17034-0","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T16:44:11Z","timestamp":1740069851000},"page":"4151-4160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Impact of Preoperative Invasive Nodal Staging on Unexpected Mediastinal Upstaging in Early-Stage Non-small Cell Lung Cancer"],"prefix":"10.1245","volume":"32","author":[{"given":"Kian C.","family":"Banks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varada","family":"Sarovar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel K.","family":"Wile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine E.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey B.","family":"Velotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"issue":"12","key":"17034_CR1","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1097\/JTO.0b013e31827457db","volume":"7","author":"RU Osarogiagbon","year":"2012","unstructured":"Osarogiagbon RU, Yu X. Mediastinal lymph node examination and survival in resected early-stage non\u2013small-cell lung cancer in the surveillance, epidemiology, and end results database. J Thorac Oncol. 2012;7(12):1798\u2013806. https:\/\/doi.org\/10.1097\/JTO.0b013e31827457db.","journal-title":"J Thorac Oncol."},{"key":"17034_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.lungcan.2020.02.008","volume":"142","author":"JE Bousema","year":"2020","unstructured":"Bousema JE, Heineman DJ, Dijkgraaf MGW, Annema JT, Van Den Broek FJC. Adherence to the mediastinal staging guideline and unforeseen N2 disease in patients with resectable non-small cell lung cancer: nationwide results from the Dutch lung cancer audit-surgery. Lung Cancer. 2020;142:51\u20138. https:\/\/doi.org\/10.1016\/j.lungcan.2020.02.008.","journal-title":"Lung Cancer."},{"issue":"4","key":"17034_CR3","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.athoracsur.2018.05.012","volume":"106","author":"SB Krantz","year":"2018","unstructured":"Krantz SB, Howington JA, Wood DE, et al. Invasive mediastinal staging for lung cancer by the society of thoracic surgeons database participants. Ann Thorac Surg. 2018;106(4):1055\u201362. https:\/\/doi.org\/10.1016\/j.athoracsur.2018.05.012.","journal-title":"Ann Thorac Surg."},{"key":"17034_CR4","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","volume":"28","author":"PE Postmus","year":"2017","unstructured":"Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv1\u201321. https:\/\/doi.org\/10.1093\/annonc\/mdx222.","journal-title":"Ann Oncol."},{"key":"17034_CR5","unstructured":"Non-Small Cell Lung Cancer: NCCN Clinical Practice Guidelines in Oncology. Published online 16 March 2022. Available at: https:\/\/www.cms.gov\/newsroom\/press-releases\/cms-expands-coverage-lung-cancer-screening-low-dose-computed-tomography#:~:text=Today%20the%20Centers%20for%20Medicare,for%20people%20with%20lung%20cancer. Accessed 1 Jul 2022."},{"issue":"2","key":"17034_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cllc.2011.08.002","volume":"13","author":"J Wang","year":"2012","unstructured":"Wang J, Welch K, Wang L, Kong FM. Negative predictive value of positron emission tomography and computed tomography for stage T1\u20132N0 non\u2013small-cell lung cancer: a meta-analysis. Clin Lung Cancer. 2012;13(2):81\u20139. https:\/\/doi.org\/10.1016\/j.cllc.2011.08.002.","journal-title":"Clin Lung Cancer."},{"key":"17034_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009519.pub2","author":"M Schmidt-Hansen","year":"2014","unstructured":"Schmidt-Hansen M, Baldwin DR, Hasler E, Zamora J, Abraira V, Figuls MRI. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. Cochrane Database Syst Rev. 2014. https:\/\/doi.org\/10.1002\/14651858.CD009519.pub2.","journal-title":"Cochrane Database Syst Rev."},{"issue":"5","key":"17034_CR8","doi-asserted-by":"publisher","first-page":"e211S","DOI":"10.1378\/chest.12-2355","volume":"143","author":"GA Silvestri","year":"2013","unstructured":"Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer. Chest. 2013;143(5):e211S-e250S. https:\/\/doi.org\/10.1378\/chest.12-2355.","journal-title":"Chest."},{"issue":"13","key":"17034_CR9","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.3390\/cancers15133475","volume":"15","author":"WK Hui","year":"2023","unstructured":"Hui WK, Charaf Z, Hendriks JMH, Van Schil PE. True prevalence of unforeseen N2 disease in NSCLC: a systematic review + meta-analysis. Cancers. 2023;15(13):3475. https:\/\/doi.org\/10.3390\/cancers15133475.","journal-title":"Cancers."},{"issue":"9","key":"17034_CR10","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1093\/oncolo\/oyad125","volume":"28","author":"AO John","year":"2023","unstructured":"John AO, Ramnath N. Neoadjuvant versus adjuvant systemic therapy for early-stage non-small cell lung cancer: the changing landscape due to immunotherapy. The Oncologist. 2023;28(9):752\u201364. https:\/\/doi.org\/10.1093\/oncolo\/oyad125.","journal-title":"The Oncologist."},{"issue":"3","key":"17034_CR11","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.chest.2019.09.021","volume":"157","author":"FC Verdial","year":"2020","unstructured":"Verdial FC, Berfield KS, Wood DE, et al. Safety and costs of endobronchial ultrasound-guided nodal aspiration and mediastinoscopy. Chest. 2020;157(3):686\u201393. https:\/\/doi.org\/10.1016\/j.chest.2019.09.021.","journal-title":"Chest."},{"issue":"22","key":"17034_CR12","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/JCO.22.01728","volume":"41","author":"JE Bousema","year":"2023","unstructured":"Bousema JE, Dijkgraaf MGW, Van Der Heijden EHFM, et al. Endosonography with or without confirmatory mediastinoscopy for resectable lung cancer: a randomized clinical trial. J Clin Oncol. 2023;41(22):3805\u201315. https:\/\/doi.org\/10.1200\/JCO.22.01728.","journal-title":"J Clin Oncol."},{"issue":"1","key":"17034_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/resp.13162","volume":"23","author":"MR Vial","year":"2018","unstructured":"Vial MR, O\u2019Connell OJ, Grosu HB, et al. Diagnostic performance of endobronchial ultrasound-guided mediastinal lymph node sampling in early stage non-small cell lung cancer: a prospective study. Respirology. 2018;23(1):76\u201381. https:\/\/doi.org\/10.1111\/resp.13162.","journal-title":"Respirology."},{"issue":"11","key":"17034_CR14","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1513\/AnnalsATS.202004-294RL","volume":"17","author":"J Guinde","year":"2020","unstructured":"Guinde J, Bourdages-Pageau E, Collin-Castonguay MM, et al. Endobronchial ultrasound for staging of the radiologically normal mediastinum: should we individualize our approach? Ann Am Thorac Soc. 2020;17(11):1493\u20136. https:\/\/doi.org\/10.1513\/AnnalsATS.202004-294RL.","journal-title":"Ann Am Thorac Soc."},{"issue":"6","key":"17034_CR15","doi-asserted-by":"publisher","first-page":"1701493","DOI":"10.1183\/13993003.01493-2017","volume":"50","author":"H Decaluw\u00e9","year":"2017","unstructured":"Decaluw\u00e9 H, Dooms C, D\u2019Journo XB, et al. Mediastinal staging by videomediastinoscopy in clinical N1 non-small cell lung cancer: a prospective multicentre study. Eur Respir J. 2017;50(6):1701493. https:\/\/doi.org\/10.1183\/13993003.01493-2017.","journal-title":"Eur Respir J."},{"issue":"20","key":"17034_CR16","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1001\/jama.2010.1705","volume":"304","author":"JT Annema","year":"2010","unstructured":"Annema JT, van Meerbeeck JP, Rintoul RC, et al. Mediastinoscopy versus endosonography for mediastinal nodal staging of lung cancer: a randomized trial. JAMA. 2010;304(20):2245\u201352.","journal-title":"JAMA."},{"issue":"2","key":"17034_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.7812\/TPP\/22.172","volume":"27","author":"AC Davis","year":"2023","unstructured":"Davis AC, Voelkel JL, Remmers CL, Adams JL, McGlynn EA. Comparing kaiser permanente members to the general population: implications for generalizability of research. Perm J. 2023;27(2):87\u201398. https:\/\/doi.org\/10.7812\/TPP\/22.172.","journal-title":"Perm J."},{"issue":"1","key":"17034_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.athoracsur.2021.05.051","volume":"113","author":"AP Nissen","year":"2022","unstructured":"Nissen AP, Vreeland TJ, Teshome M, et al. American college of surgeons commission on cancer standard for curative-intent pulmonary resection. Ann Thorac Surg. 2022;113(1):5\u20138. https:\/\/doi.org\/10.1016\/j.athoracsur.2021.05.051.","journal-title":"Ann Thorac Surg."},{"issue":"1","key":"17034_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jamaoncol.2017.2993","volume":"4","author":"MP Smeltzer","year":"2018","unstructured":"Smeltzer MP, Faris NR, Ray MA, Osarogiagbon RU. Association of pathologic nodal staging quality with survival among patients with non-small cell lung cancer after resection with curative intent. JAMA Oncol. 2018;4(1):80. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2993.","journal-title":"JAMA Oncol."},{"issue":"1","key":"17034_CR20","doi-asserted-by":"publisher","DOI":"10.1117\/1.JMI.4.1.011013","volume":"4","author":"T Jones","year":"2017","unstructured":"Jones T, Townsend D. History and future technical innovation in positron emission tomography. J Med Imaging. 2017;4(1):011013. https:\/\/doi.org\/10.1117\/1.JMI.4.1.011013.","journal-title":"J Med Imaging."},{"issue":"1","key":"17034_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1183\/09031936.00035108","volume":"33","author":"W De Wever","year":"2009","unstructured":"De Wever W, Stroobants S, Coolen J, Verschakelen JA. Integrated PET\/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur Respir J. 2009;33(1):201\u201312. https:\/\/doi.org\/10.1183\/09031936.00035108.","journal-title":"Eur Respir J."},{"key":"17034_CR22","doi-asserted-by":"publisher","first-page":"1184448","DOI":"10.3389\/fnume.2023.1184448","volume":"3","author":"F Butt","year":"2023","unstructured":"Butt F, Dominguez-Konicki L, Tocci N, Paydarfar J, Seltzer M, Pastel D. Diagnostic accuracy of latest generation digital PET\/CT scanner for detection of metastatic lymph nodes in head and neck cancer. Front Nucl Med. 2023;3:1184448. https:\/\/doi.org\/10.3389\/fnume.2023.1184448.","journal-title":"Front Nucl Med."},{"key":"17034_CR23","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_389950","volume":"43","author":"D O\u2019Reilly","year":"2023","unstructured":"O\u2019Reilly D, Botticella A, Barry S, et al. Treatment decisions for resectable non\u2013small-cell lung cancer: balancing less with more? Am Soc Clin Oncol Educ Book. 2023;43:e389950. https:\/\/doi.org\/10.1200\/EDBK_389950.","journal-title":"Am Soc Clin Oncol Educ Book."},{"issue":"10","key":"17034_CR24","doi-asserted-by":"publisher","first-page":"818.e17","DOI":"10.1016\/j.crad.2019.07.009","volume":"74","author":"DD Yang","year":"2019","unstructured":"Yang DD, Mirvis E, Goldring J, Patel ARC, Wagner T. Improving diagnostic performance of 18F-FDG-PET\/CT for assessment of regional nodal involvement in non-small cell lung cancer. Clin Radiol. 2019;74(10):818.e17-818.e23. https:\/\/doi.org\/10.1016\/j.crad.2019.07.009.","journal-title":"Clin Radiol."},{"issue":"6","key":"17034_CR25","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1097\/JTO.0000000000000546","volume":"10","author":"T Haruki","year":"2015","unstructured":"Haruki T, Aokage K, Miyoshi T, et al. Mediastinal nodal involvement in patients with clinical stage I non\u2013small-cell lung cancer: possibility of rational lymph node dissection. J Thorac Oncol. 2015;10(6):930\u20136. https:\/\/doi.org\/10.1097\/JTO.0000000000000546.","journal-title":"J Thorac Oncol."},{"issue":"4","key":"17034_CR26","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/ejcts\/ezw400","volume":"51","author":"A Bille","year":"2017","unstructured":"Bille A, Woo KM, Ahmad U, Rizk NP, Jones DR. Incidence of occult pN2 disease following resection and mediastinal lymph node dissection in clinical stage I lung cancer patients. Eur J Cardiothorac Surg. 2017;51(4):674\u20139. https:\/\/doi.org\/10.1093\/ejcts\/ezw400.","journal-title":"Eur J Cardiothorac Surg."},{"issue":"1","key":"17034_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jtcvs.2008.09.045","volume":"137","author":"BM Stiles","year":"2009","unstructured":"Stiles BM, Servais EL, Lee PC, Port JL, Paul S, Altorki NK. POINT: Clinical stage IA non\u2013small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non\u2013small cell lung cancer: the problem of understaging. J Thorac Cardiovasc Surg. 2009;137(1):13\u20139. https:\/\/doi.org\/10.1016\/j.jtcvs.2008.09.045.","journal-title":"J Thorac Cardiovasc Surg."},{"issue":"2","key":"17034_CR28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.athoracsur.2012.04.059","volume":"94","author":"DJ Boffa","year":"2012","unstructured":"Boffa DJ, Kosinski AS, Paul S, Mitchell JD, Onaitis M. Lymph node evaluation by open or video-assisted approaches in 11,500 anatomic lung cancer resections. Ann Thorac Surg. 2012;94(2):347\u201353. https:\/\/doi.org\/10.1016\/j.athoracsur.2012.04.059.","journal-title":"Ann Thorac Surg."},{"issue":"3","key":"17034_CR29","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.athoracsur.2013.04.011","volume":"96","author":"PB Licht","year":"2013","unstructured":"Licht PB, J\u00f8rgensen OD, Ladegaard L, Jakobsen E. A National study of nodal upstaging after thoracoscopic versus open lobectomy for clinical stage I lung cancer. Ann Thorac Surg. 2013;96(3):943\u201350. https:\/\/doi.org\/10.1016\/j.athoracsur.2013.04.011.","journal-title":"Ann Thorac Surg."},{"issue":"5","key":"17034_CR30","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.athoracsur.2017.01.098","volume":"103","author":"RU Osarogiagbon","year":"2017","unstructured":"Osarogiagbon RU, Ray MA, Faris NR, et al. Prognostic value of national comprehensive cancer network lung cancer resection quality criteria. Ann Thorac Surg. 2017;103(5):1557\u201365. https:\/\/doi.org\/10.1016\/j.athoracsur.2017.01.098.","journal-title":"Ann Thorac Surg."},{"issue":"12","key":"17034_CR31","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","volume":"7","author":"AK Ganti","year":"2021","unstructured":"Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US. JAMA Oncol. 2021;7(12):1824. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4932.","journal-title":"JAMA Oncol."},{"issue":"8 Suppl","key":"17034_CR32","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1200\/JCO.2017.35.8_suppl.192","volume":"35","author":"KL Mackenney","year":"2017","unstructured":"Mackenney KL, Faiz S, Larson AJ, Eapen GA, Bashoura L. Decreasing wait times for endobronchial ultrasound (EBUS). J Clin Oncol. 2017;35(8 Suppl):192. https:\/\/doi.org\/10.1200\/JCO.2017.35.8_suppl.192.","journal-title":"J Clin Oncol."},{"issue":"9","key":"17034_CR33","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.jtho.2017.05.023","volume":"12","author":"M Evison","year":"2017","unstructured":"Evison M, Clive A, Castle L, et al. Resectable clinical N2 non-small cell lung cancer; what is the optimal treatment strategy? An update by the british thoracic society lung cancer specialist advisory group. J Thorac Oncol. 2017;12(9):1434\u201341. https:\/\/doi.org\/10.1016\/j.jtho.2017.05.023.","journal-title":"J Thorac Oncol."},{"issue":"5","key":"17034_CR34","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/ejcts\/ezt478","volume":"45","author":"T Tsitsias","year":"2014","unstructured":"Tsitsias T, Boulemden A, Ang K, Nakas A, Waller DA. The N2 paradox: similar outcomes of pre- and postoperatively identified single-zone N2a positive non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;45(5):882\u20137. https:\/\/doi.org\/10.1093\/ejcts\/ezt478.","journal-title":"Eur J Cardiothorac Surg."},{"issue":"10","key":"17034_CR35","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1001\/jamaoncol.2023.2751","volume":"9","author":"J Lei","year":"2023","unstructured":"Lei J, Zhao J, Gong L, et al. Neoadjuvant camrelizumab plus platinum-based chemotherapy vs chemotherapy alone for Chinese patients with resectable stage IIIA or IIIB (T3N2) non-small cell lung cancer: the TD-FOREKNOW randomized clinical trial. JAMA Oncol. 2023;9(10):1348. https:\/\/doi.org\/10.1001\/jamaoncol.2023.2751.","journal-title":"JAMA Oncol."},{"issue":"21","key":"17034_CR36","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2202170.","journal-title":"N Engl J Med."},{"key":"17034_CR37","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1200\/EDBK_358995","volume":"42","author":"M Provencio","year":"2022","unstructured":"Provencio M, Calvo V, Romero A, Spicer JD, Cruz-Berm\u00fadez A. Treatment sequencing in resectable lung cancer: the good and the bad of adjuvant versus neoadjuvant therapy. Am Soc Clin Oncol Educ Book. 2022;42:711\u201328. https:\/\/doi.org\/10.1200\/EDBK_358995.","journal-title":"Am Soc Clin Oncol Educ Book."},{"issue":"1","key":"17034_CR38","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40644-023-00540-3","volume":"23","author":"I Alberts","year":"2023","unstructured":"Alberts I, Sari H, Mingels C, et al. Long-axial field-of-view PET\/CT: perspectives and review of a revolutionary development in nuclear medicine based on clinical experience in over 7000 patients. Cancer Imaging. 2023;23(1):28. https:\/\/doi.org\/10.1186\/s40644-023-00540-3.","journal-title":"Cancer Imaging."},{"issue":"3","key":"17034_CR39","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.chest.2021.04.048","volume":"160","author":"G Martinez-Zayas","year":"2021","unstructured":"Martinez-Zayas G, Almeida FA, Yarmus L, et al. Predicting lymph node metastasis in non-small cell lung cancer. Chest. 2021;160(3):1108\u201320. https:\/\/doi.org\/10.1016\/j.chest.2021.04.048.","journal-title":"Chest."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17034-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17034-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17034-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T16:14:43Z","timestamp":1746288883000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17034-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["17034"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17034-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"26 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jeffrey B. Velotta has received research funding from AstraZeneca, unrelated to this work, which has been awarded directly to his institution. Varada Sarovar, Kian C. Banks, Angela Sun, Rachel K. Wile, and Katherine E. Barnes have no other known competing financial or personal relationships that could have appeared to influence the work reported in this paper. The funding source had no role in designing the study, collecting, analyzing and interpreting the data, writing the report, or making the decision to submit for publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}